Physician profile
Andrew Lawrence Smith
NPI 1518251198
$254,337.54
in general payments reported to CMS, 2019-2025
15 companies · $54K in 2025
The $54K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $20K · 2021: $12K · 2022: $35K · 2023: $26K · 2024: $43K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $94K · Consulting Fee: $14K · Travel and Lodging: $7,722 · Food and Beverage: $6,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $94,430.00 |
| Consulting Fee | $13,968.00 |
| Travel and Lodging | $7,722.46 |
| Food and Beverage | $6,371.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $132,680.05 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $27,997.84 | 2019-2022 | |
| Genentech USA, INC. | $26,460.58 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $25,488.07 | 2024-2025 | Ultomiris |
| Genzyme Corporation | $20,415.72 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $14,772.41 | 2019-2024 | |
| Tg Therapeutics, INC. | $2,242.44 | 2022-2025 | |
| Celgene Corporation | $1,534.74 | 2019-2025 | Zeposia |
| Medtronic, INC. | $1,078.68 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $900.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $293.28 | 2021-2022 | |
| Horizon Therapeutics Plc | $169.70 | 2022-2023 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $167.28 | 2023 | Zeposia |
| Amgen INC. | $114.75 | 2024 | Uplizna |
| Impel Pharmaceuticals INC. | $22.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.